Terns Pharmaceuticals, Inc. — Director's Dealing 2024

Sep 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2024-09-12

Reporting Person: Lu Hongbo (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-12	Common Stock	P	190476	$10.50	Acquired	190476	Indirect
2024-09-12	Common Stock	P	285714	$10.50	Acquired	476190	Indirect

Footnotes

F1: The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.